Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine in Advanced or Recurrent Squamous Cell Carcinoma of the Skin
NCT01823679Phase 2Terminated
- Sponsor
- Stanford University
- Start
- Mar 2013
- Primary completion
- May 2014
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in squamous cell carcinoma of the skin (SCC), sponsored by Stanford University. Started Mar 2013; status: terminated.
02
Drugs
capecitabine
03
Conditions
squamous cell carcinoma of the skin (SCC)
Beyond the preview
Go deeper on NCT01823679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01823679.